Saturday, July 11, 2026

pharma · Influenza immunisation

Abott Laboratories

Abbott Laboratories is a pharma organization headquartered in Moscow, RU. Primary therapeutic focus areas include Influenza immunisation. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record

Moscow, RU HQ
576 Employees
EMA registrant Type
Company details
Clinical program

INFQ-324-0476

Phase 3 · small molecule · Influenza immunisation

INFQ-324-0476 for Influenza immunisation is a Phase 3 program (small_molecule) at Abbott Laboratories with 1 ClinicalTrials.gov record(s).

← All Abbott Laboratories projects Phase 3 small molecule active

Internal code INFQ-324-0476

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Abbott Laboratories
Phase
Phase 3
Modality
small_molecule
Indication
Influenza immunisation
Status
active
Trials
1